MMA Embolization for Refractory Chronic Migraine
- Conditions
- Migraine
- Registration Number
- NCT06735833
- Lead Sponsor
- Cerenovus, Part of DePuy Synthes Products, Inc.
- Brief Summary
This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 50
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Change from baseline, in number of migraine days over 28 days
- Secondary Outcome Measures
Name Time Method Change from baseline in migraine days frequency 3 months and 6 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (5)
Mount Sinai
🇺🇸New York, New York, United States
Stony Brook University Medical Center
🇺🇸Stony Brook, New York, United States
Thomas Jefferson University Hospital
🇺🇸Philadelphia, Pennsylvania, United States
Semmes Murphey Foundation
🇺🇸Memphis, Tennessee, United States
West Virginia University
🇺🇸Morgantown, West Virginia, United States